核医学診断の世界市場レポート 2024年

核医学診断の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には11.4%の年間複合成長率（CAGR）で113億1,000万米ドルに成長すると予想されます。予測される成長は、神経学応用の拡大、統合画像モダリティ、高精度医療、セラノスティクスの需要、世界の疾病根絶への取り組みによって促進されます。主要動向には、分散型放射性医薬品、神経学における核医学使用の増加、ラジオミクス、共同研究開発、放射線安全性の強調が含まれます。

核医学診断市場の予想される成長は、これらの診断技術に対する需要の高まりによって推進されています。核医学は、病気の診断や、治療中に罹患または損傷した臓器や組織を標的として除去するために、体内の放射性物質を利用します。 核医学診断の用途は主に放射線治療やその他の救命治療です。これらの診断に対する需要が高まっているのは、正確な結果や治療の意思決定能力の強化などの利点によるものです。英国を拠点とする原子力推進の国際機関であるWorld Nuclear Associationが2022年4月に報告したように、核医学治療の年間件数は4,000万件を超え、放射性同位元素の需要は年間最大5％の成長率を記録しています。注目すべきことに、医療における放射性同位元素を含む処置の90%以上が、世界中の1万以上の病院で実施されています。この需要の急増は、核医学診断の極めて重要な役割を強調し、核医学診断市場の予想される成長に貢献しています。

核医学診断市場の予想される成長は、がんの罹患率の増加に強く影響されます。がんは、腫瘍を形成する異常細胞の制御されない増殖と広がりを特徴とし、一連の疾患の代表です。 核医学診断は、特殊なカメラで検出できる放射性物質を利用して、さまざまな種類のがんの検出、病期分類、監視に重要な役割を果たします。このプロセスにより、臓器や組織の内部構造と機能の詳細な画像が生成されます。 2023年 1月の時点で、米国に本拠を置く自主保健組織であるAmerican Cancer Society Inc.の報告書によると、がんによる死亡者数は60万6,520人です。 2021年までに、190万人が新たにがんと診断され、60万8,570人ががんにより死亡すると予測されています。このがん症例の大幅な増加は、がんによってもたらされる課題に対処する上での核医学診断の重要性を強調し、核医学診断市場の成長を促進します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の核医学診断市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の核医学診断市場規模実績と成長、2018～2023年
• 世界の核医学診断市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の核医学診断市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• SPECT放射性医薬品
• PET放射性医薬品
• 世界の核医学診断市場、用途別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 心臓病学
• 甲状腺
• 神経内科
• 腫瘍学
• その他
• 世界の核医学診断市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院と診断センター
• 研究機関

第7章 地域と国の分析

• 世界の核医学診断市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の核医学診断市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 核医学診断市場の競合情勢
• 核医学診断市場の企業プロファイル
  • Siemens AG
  • Bayer Aktiengesellschaft
  • Novartis AG
  • GE Healthcare Technologies Inc.
  • Perkin Elmer Inc.

第31章 その他の主要と革新的な企業

• Mallinckrodt Pharmaceuticals
• Bracco Diagnostics Inc.
• Lantheus Holdings Inc.
• IBA Radiopharma Solutions
• Curium SAS
• Cardinal Health Inc.
• Eckert &Ziegler Strahlen-und Medizintechnik AG
• Advanced Accelerator Applications
• Telix Pharmaceuticals Limited
• Nordion (Canada) Inc.
• NorthStar Medical Technologies LLC
• SHINE Medical Technologies LLC
• Navidea Biopharmaceuticals Inc.
• Cyclopharm Limited
• Isologic Innovative Radiopharmaceuticals

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Nuclear medicine employs radioactive substances administered internally to diagnose illnesses or selectively target and eliminate diseased or damaged organs and tissues during treatment. This field encompasses the utilization of radioactive drugs for research, therapeutic, and diagnostic objectives. In diagnostic nuclear medicine, radioactive tracers are employed to visualize and/or measure the overall or localized function of specific organs, providing valuable insights for medical diagnosis and treatment planning.

The primary categories of nuclear medicine diagnostics encompass SPECT radiopharmaceuticals and PET radiopharmaceuticals. SPECT Radiopharmaceuticals, or single-photon emission computerized tomography, pertain to gamma-ray tomographic imaging techniques employed in the field of nuclear medicine. These methods find application in diverse medical areas such as cardiology, thyroid, neurology, oncology, among others. End-users of these diagnostic technologies include hospitals, diagnostic centers, and research institutes.

The nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides nuclear medicine diagnostics market statistics, including nuclear medicine diagnostics industry global market size, regional shares, competitors with nuclear medicine diagnostics market share, detailed nuclear medicine diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the nuclear medicine diagnostics industry. This nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $6.57 billion in 2023 to $7.34 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. Historical growth can be linked to advancements in medical imaging, rising chronic disease rates, trends in an aging population, clinical applications in oncology, and the pursuit of diagnostic accuracy and precision.

The nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $11.31 billion in 2028 at a compound annual growth rate (CAGR) of 11.4%. Forecasted growth is spurred by expanding neurology applications, integrated imaging modalities, precision medicine, theranostics demand, and global disease eradication efforts. Key trends involve decentralized radiopharmacy, increased nuclear medicine use in neurology, radiomics, collaborative R&D, and emphasized radiation safety.

The anticipated growth of the nuclear medicine diagnostics market is driven by a rising demand for these diagnostic techniques. Nuclear medicine utilizes radioactive substances within the body for diagnosing illnesses and for targeted removal of diseased or damaged organs and tissues during treatment. The applications of nuclear medicine diagnostics are predominantly in radiation and other life-saving treatments. The increasing demand for these diagnostics is attributed to their advantages, including accurate results and enhanced treatment decision-making capabilities. As reported in April 2022 by the World Nuclear Association, a UK-based international organization advocating for nuclear power, the annual number of nuclear medicine treatments surpasses 40 million, with the demand for radioisotopes witnessing a yearly growth rate of up to 5%. Notably, over 90% of procedures involving radioisotopes in medicine are conducted in more than 10,000 hospitals worldwide. This surge in demand underscores the pivotal role of nuclear medicine diagnostics, contributing to the anticipated growth of the nuclear medicine diagnostics market.

The anticipated growth of the nuclear medicine diagnostics market is strongly influenced by the increasing prevalence of cancer. Cancer, characterized by the uncontrolled growth and spread of abnormal cells forming tumors, represents a group of diseases. Nuclear medicine diagnostics play a crucial role in the detection, staging, and monitoring of various types of cancer, utilizing radioactive substances detectable by specialized cameras. This process generates detailed images of internal structures and functions of organs and tissues. As of January 2023, reports from the American Cancer Society Inc., a US-based voluntary health organization, indicated 606,520 cancer fatalities. By 2021, it is projected that there will be 1.9 million new cancer cases diagnosed and 608,570 cancer deaths. This substantial increase in cancer cases underscores the significance of nuclear medicine diagnostics in addressing the challenges posed by cancer, thus driving the growth of the nuclear medicine diagnostics market.

Prominent companies in the nuclear medicine diagnostics market are strategically focusing on the introduction of advanced solutions, particularly advanced medical technologies, to establish a competitive advantage. Advanced medical technologies represent cutting-edge innovations within the medical field, aimed at improving patient outcomes, elevating the standard of care, and fostering overall health improvement. An illustrative example is Gleneagles Hospital, a Malaysia-based company providing medical and healthcare services. In August 2023, the hospital introduced a Nuclear Medicine Unit, showcasing its commitment to advanced medical technologies. This specialized unit, equipped with state-of-the-art technology and staffed by highly skilled professionals, is designed to facilitate early detection, diagnosis, and treatment of diseases through nuclear medicine imaging techniques. Such initiatives by major companies underscore the industry's dedication to advancing technology and enhancing medical capabilities within the nuclear medicine diagnostics market.

Major companies in the nuclear medicine diagnostics market are actively pursuing strategic partnerships as a key approach to securing a competitive edge. Strategic partnerships involve collaborative efforts between two or more entities with the goal of achieving mutually advantageous objectives by combining resources and expertise. A noteworthy example occurred in June 2023, where RLS Inc., a US-based nuclear medicine provider, entered into a strategic partnership with SOFIE, a US-based molecular imaging company. Through this collaboration, RLS Inc. aims to enhance the distribution of nuclear medicine doses to patients, hospitals, teaching institutions, and doctors, thereby improving the overall continuum of care for patients. This strategic partnership will streamline patient dose preparation, capitalizing on the accredited radiopharmacy network and expertise of both entities involved. Such initiatives underscore the industry's commitment to fostering collaboration and leveraging collective strengths to drive advancements in the nuclear medicine diagnostics market.

In January 2022, Eckert & Ziegler, a Germany-based provider of isotope technology for medical, scientific, and industrial applications, successfully acquired Tecnonuclear SA for an undisclosed sum. This strategic acquisition positions Eckert & Ziegler to broaden its footprint and enhance essential healthcare services in Brazil and across South America. Tecnonuclear SA, an Argentina-based specialist in nuclear medicine, brings valuable expertise and resources to strengthen Eckert & Ziegler's presence in the region, aligning with the company's commitment to advancing isotope technology for medical applications.

Major companies operating in the nuclear medicine diagnostics market report are Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Cardinal Health Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp., Institute of Isotopes Co. Ltd., Global Medical Solutions LLC, Theragnostics Ltd., Sirona Complete Care, Nordic Nanovector ASA, EczacIbasI-Monrol Nuclear Products Co.

North America was the largest region in the nuclear medicine diagnostics market in 2023. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nuclear medicine diagnostics market consists of sales of renal scan, bone scan, gallium scan, heart scan, brain scan and breast scan diagnostics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Medicine Diagnostics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nuclear medicine diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nuclear medicine diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: SPECT Radiopharmaceuticals; PET Radiopharmaceuticals
• 2) By Application: Cardiology; Thyroid; Neurology; Oncology; Other Applications
• 3) By End-User: Hospitals And Diagnostic Centers; Research Institutes
• Companies Mentioned: Siemens AG; Bayer Aktiengesellschaft; Novartis AG; GE Healthcare Technologies Inc.; Perkin Elmer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nuclear Medicine Diagnostics Market Characteristics

3. Nuclear Medicine Diagnostics Market Trends And Strategies

4. Nuclear Medicine Diagnostics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Nuclear Medicine Diagnostics Market Size and Growth

• 5.1. Global Nuclear Medicine Diagnostics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Nuclear Medicine Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Nuclear Medicine Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Nuclear Medicine Diagnostics Market Segmentation

• 6.1. Global Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• SPECT Radiopharmaceuticals
• PET Radiopharmaceuticals
• 6.2. Global Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Cardiology
• Thyroid
• Neurology
• Oncology
• Other Applications
• 6.3. Global Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals And Diagnostic Centers
• Research Institutes

7. Nuclear Medicine Diagnostics Market Regional And Country Analysis

• 7.1. Global Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Nuclear Medicine Diagnostics Market

• 8.1. Asia-Pacific Nuclear Medicine Diagnostics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Nuclear Medicine Diagnostics Market

• 9.1. China Nuclear Medicine Diagnostics Market Overview
• 9.2. China Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Nuclear Medicine Diagnostics Market

• 10.1. India Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Nuclear Medicine Diagnostics Market

• 11.1. Japan Nuclear Medicine Diagnostics Market Overview
• 11.2. Japan Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Nuclear Medicine Diagnostics Market

• 12.1. Australia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Nuclear Medicine Diagnostics Market

• 13.1. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Nuclear Medicine Diagnostics Market

• 14.1. South Korea Nuclear Medicine Diagnostics Market Overview
• 14.2. South Korea Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Nuclear Medicine Diagnostics Market

• 15.1. Western Europe Nuclear Medicine Diagnostics Market Overview
• 15.2. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Nuclear Medicine Diagnostics Market

• 16.1. UK Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Nuclear Medicine Diagnostics Market

• 17.1. Germany Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Nuclear Medicine Diagnostics Market

• 18.1. France Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Nuclear Medicine Diagnostics Market

• 19.1. Italy Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Nuclear Medicine Diagnostics Market

• 20.1. Spain Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Nuclear Medicine Diagnostics Market

• 21.1. Eastern Europe Nuclear Medicine Diagnostics Market Overview
• 21.2. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Nuclear Medicine Diagnostics Market

• 22.1. Russia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Nuclear Medicine Diagnostics Market

• 23.1. North America Nuclear Medicine Diagnostics Market Overview
• 23.2. North America Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Nuclear Medicine Diagnostics Market

• 24.1. USA Nuclear Medicine Diagnostics Market Overview
• 24.2. USA Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Nuclear Medicine Diagnostics Market

• 25.1. Canada Nuclear Medicine Diagnostics Market Overview
• 25.2. Canada Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Nuclear Medicine Diagnostics Market

• 26.1. South America Nuclear Medicine Diagnostics Market Overview
• 26.2. South America Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Nuclear Medicine Diagnostics Market

• 27.1. Brazil Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Nuclear Medicine Diagnostics Market

• 28.1. Middle East Nuclear Medicine Diagnostics Market Overview
• 28.2. Middle East Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Nuclear Medicine Diagnostics Market

• 29.1. Africa Nuclear Medicine Diagnostics Market Overview
• 29.2. Africa Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Nuclear Medicine Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Nuclear Medicine Diagnostics Market Competitive Landscape
• 30.2. Nuclear Medicine Diagnostics Market Company Profiles
  • 30.2.1. Siemens AG
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Bayer Aktiengesellschaft
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. GE Healthcare Technologies Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Perkin Elmer Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Nuclear Medicine Diagnostics Market Other Major And Innovative Companies

• 31.1. Mallinckrodt Pharmaceuticals
• 31.2. Bracco Diagnostics Inc.
• 31.3. Lantheus Holdings Inc.
• 31.4. IBA Radiopharma Solutions
• 31.5. Curium SAS
• 31.6. Cardinal Health Inc.
• 31.7. Eckert & Ziegler Strahlen- und Medizintechnik AG
• 31.8. Advanced Accelerator Applications
• 31.9. Telix Pharmaceuticals Limited
• 31.10. Nordion (Canada) Inc.
• 31.11. NorthStar Medical Technologies LLC
• 31.12. SHINE Medical Technologies LLC
• 31.13. Navidea Biopharmaceuticals Inc.
• 31.14. Cyclopharm Limited
• 31.15. Isologic Innovative Radiopharmaceuticals

32. Global Nuclear Medicine Diagnostics Market Competitive Benchmarking

33. Global Nuclear Medicine Diagnostics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Nuclear Medicine Diagnostics Market

35. Nuclear Medicine Diagnostics Market Future Outlook and Potential Analysis

• 35.1 Nuclear Medicine Diagnostics Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Nuclear Medicine Diagnostics Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Nuclear Medicine Diagnostics Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer